TY - JOUR
T1 - Neutropenic Enterocolitis
T2 - Clinical Features and Outcomes
AU - Abu-Sbeih, Hamzah
AU - Ali, Faisal S.
AU - Chen, Ellie
AU - Mallepally, Niharika
AU - Luo, Wenyi
AU - Lu, Yang
AU - Foo, Wai Chin
AU - Qiao, Wei
AU - Okhuysen, Pablo C.
AU - Adachi, Javier A.
AU - Hachem, Ray Y.
AU - Altan, Mehmet
AU - Jenq, Robert R.
AU - Wang, Yinghong
N1 - Publisher Copyright:
© The 2019 ASCRS.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background: Patients undergoing chemotherapy are at risk for mucosal injury and neutropenia, which facilitate colonic mucosal invasion by the bowel flora and subsequent neutropenic enterocolitis, which has a poor prognosis. Objective: This study aimed to assess the clinical features and outcomes of neutropenic enterocolitis in patients at a comprehensive cancer center. Design: This is a retrospective cohort study. Setting: The study was conducted at the University of Texas MD Anderson Cancer Center. Patients: Neutropenic enterocolitis was defined by the presence of an absolute neutrophil count <1000/mm3, compatible abdominal symptoms, and either mucosal thickening on abdominal imaging or mucosal injury on colon biopsy. Patients who had been diagnosed between 2010 and 2018 were included. MAIN OUTCOMES: Complication and survival rates were analyzed using logistic regression and Cox regression analyses, respectively. Results: Of the 49,244 patients who had neutropenia during the study period, 134 (2.7%) were included. The median time from neutropenia onset to neutropenic enterocolitis was 2 days (interquartile range, 1-10 days). Neutropenic enterocolitis symptoms lasted for a median of 11 days (interquartile range, 6-22 days). Most patients received antibiotics (88%) and granulocyte colony-stimulating factor (68%). Complications included sepsis (11%), colonic perforation (2%), pneumatosis intestinalis (2%), and abscess formation (2%). The risks associated with complications included immunosuppressive therapy use within 1 month before neutropenic enterocolitis onset (OR, 3.92; 95% CI, 1.04-14.76) and delayed imaging (OR, 1.10; 95% CI, 1.03-1.17). Older age, severe neutropenia, prolonged neutropenia before and after neutropenic enterocolitis diagnosis, and other concomitant systemic infections were associated with lower survival rates. Limitations: The performance of this study at a single center and its retrospective nature are limitations of the study. Conclusion: The prompt diagnosis and management of neutropenic enterocolitis are critical to prevent complications. The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
AB - Background: Patients undergoing chemotherapy are at risk for mucosal injury and neutropenia, which facilitate colonic mucosal invasion by the bowel flora and subsequent neutropenic enterocolitis, which has a poor prognosis. Objective: This study aimed to assess the clinical features and outcomes of neutropenic enterocolitis in patients at a comprehensive cancer center. Design: This is a retrospective cohort study. Setting: The study was conducted at the University of Texas MD Anderson Cancer Center. Patients: Neutropenic enterocolitis was defined by the presence of an absolute neutrophil count <1000/mm3, compatible abdominal symptoms, and either mucosal thickening on abdominal imaging or mucosal injury on colon biopsy. Patients who had been diagnosed between 2010 and 2018 were included. MAIN OUTCOMES: Complication and survival rates were analyzed using logistic regression and Cox regression analyses, respectively. Results: Of the 49,244 patients who had neutropenia during the study period, 134 (2.7%) were included. The median time from neutropenia onset to neutropenic enterocolitis was 2 days (interquartile range, 1-10 days). Neutropenic enterocolitis symptoms lasted for a median of 11 days (interquartile range, 6-22 days). Most patients received antibiotics (88%) and granulocyte colony-stimulating factor (68%). Complications included sepsis (11%), colonic perforation (2%), pneumatosis intestinalis (2%), and abscess formation (2%). The risks associated with complications included immunosuppressive therapy use within 1 month before neutropenic enterocolitis onset (OR, 3.92; 95% CI, 1.04-14.76) and delayed imaging (OR, 1.10; 95% CI, 1.03-1.17). Older age, severe neutropenia, prolonged neutropenia before and after neutropenic enterocolitis diagnosis, and other concomitant systemic infections were associated with lower survival rates. Limitations: The performance of this study at a single center and its retrospective nature are limitations of the study. Conclusion: The prompt diagnosis and management of neutropenic enterocolitis are critical to prevent complications. The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
KW - Colitis
KW - Neutropenia
KW - Neutropenic colitis
KW - Neutropenic enterocolitis
KW - Typhlitis
UR - http://www.scopus.com/inward/record.url?scp=85079102642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079102642&partnerID=8YFLogxK
U2 - 10.1097/DCR.0000000000001548
DO - 10.1097/DCR.0000000000001548
M3 - Article
C2 - 31842164
AN - SCOPUS:85079102642
SN - 0012-3706
VL - 63
SP - 381
EP - 388
JO - Diseases of the colon and rectum
JF - Diseases of the colon and rectum
IS - 3
ER -